DOSIsoft MU2net is FDA 510(k) Cleared for Patient QA – Secondary Dose Calculation
- November 7, 2019
DOSIsoft, leading provider of patient-specific software solutions for Radiation Oncology and Nuclear Medicine, is pleased to announce that on October 24th, 2019, it received 510(k) clearance from the US Food and Drug Administration (FDA), to market MU2net, software dedicated to Independent Secondary Dose Calculation for Patient Quality Assurance (QA).
[Elekta’s PR] Elekta announces Exclusive Agreement with DOSIsoft for Distribution of Key Patient Specific QA Solutions
- September 5, 2019
Products fill out company’s Elekta Assurance portfolio for comprehensive end-to-end quality assurance.
DOSIsoft PLANET® Onco Dose Receives FDA 510(k) Clearance for Molecular Imaging & Molecular Radiotherapy Dosimetry
- March 12, 2019
DOSIsoft announces it has received on March 7th, 2019, from the US Food and Drug Administration (FDA), the 510(k) clearance to market PLANET® Onco Dose software, for its Oncology and Yttrium-90 microsphere SIRT 3D Dosimetry components.
Léon Bérard Center has selected EPIbeam, The EPID-based pretreatment patient-specific Quality Assurance software solution from DOSIsoft
- February 6, 2019
DOSIsoft announces that the Léon Bérard Center (CLB, Lyon, France), has selected EPIbeam – its Patient Specific Quality Assurance (QA) Software based on the Electronic Portal Imaging Device (EPID) and dedicated to pretreatment verification of irradiation beams.
Launching new version of PLANET® Dose: CE marked Multi-radionuclide 3D Personalized Dosimetry Platform for Molecular Radiotherapy
- October 12, 2018
DOSIsoft launches a new version of PLANET® Dose – its multi-radionuclide dosimetry platform dedicated to Molecular Radiotherapy (MRT). In addition to improvements for 90Yttrium-based therapies, the new version includes the full support of 177Lutetium-based therapies. These additional developments have been performed in collaboration with the Cancer Research Center of Toulouse (CRCT) – UMR 1037 Inserm / Toulouse III – Paul Sabatier University and the Institut Jules Bordet in Brussels.
“Improving Molecular Radiotherapy” – A Collaboration Between DOSIsoft And Sylvester Comprehensive Cancer Center at the University of Miami (Florida)
- June 7, 2018
DOSIsoft, leading provider of advanced software solutions for Radiation Oncology and Nuclear Medicine, announces its academic collaboration with Sylvester Comprehensive Cancer Center at the University of Miami (Florida) on 3D personalized dosimetry for Y90-SIRT therapy. A research study was conducted using DOSIsoft PLANET® Dose software and the preliminary results will be presented at the SNMMI 2018 annual meeting.
DOSIsoft is now member of Elekta’s Third Party Vendor Interoperability Program (VIP)
- April 19, 2018
DOSIsoft SA has entered Elekta’s Vendor Interoperability Program (VIP) ensuring the interoperability of DOSIsoft’s Quality Assurance products (EPIgray® and EPIbeam) with Elekta iViewGT™ portal image device. The software development has been carried out in 2017, and the interoperability validation program has been completed on April 6th, 2018.
Securing the Radiation Therapy Patient Treatment Path: Experimentation Results of the “EPIbeam” Quality Assurance Solution
- April 17, 2018
DOSIsoft and Unicancer, which groups together all French Comprehensive Cancer Centers (FCCCs), established a scientific partnership with EPIbeam software aiming to optimize patient safety in Radiation Therapy. An experiment in real conditions was carried out successfully in 2017 in 7 FCCCs and demonstrated the accuracy and ability of EPIbeam to reliably perform pretreatment controls in clinical routine.
DOSIsoft Receives FDA Clearance for ThinkQA – EPIbeam, its Pretreatment Quality Control Software
- March 20, 2018
DOSIsoft SA is proud to announce it has received 510(k) clearance, on March 13th, 2018, from the US Food and Drug Administration (FDA) for ThinkQA-EPIbeam, a modular software suite composed of EPIbeam module dedicated to Patient Specific Quality Assurance (QA) for pretreatment verification of irradiation beams.
PLANET® Dose is Selected by The French Public Hospitals for Targeted Radionuclide Therapies
- January 25, 2018
DOSIsoft SA has been selected, following a public tender, by the French public hospitals (CH and CHU), through their centralized purchasing organization UniHA, for the supply, installation and commissioning services of PLANET® Dose Software Suite dedicated to Targeted Radionuclide Therapies (90Yttrium microspheres SIRT / 177Lutetium based treatments) in Nuclear Medicine.